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Asthma is a common respiratory disease that is characterized by variable airways obstruction caused by acute and
chronic bronchial inflammation; associated phenotypes include bronchial hyperresponsiveness (BHR), elevated total
serum immunoglobulin E (IgE) levels, and skin tests positive to common allergens. Binding of interleukin-13 (IL13)
or interleukin-4 (IL4) to the IL4 receptor (IL4R) induces the initial response for Th2 lymphocyte polarization. Both
IL13 and IL4 are produced by Th2 cells and are capable of inducing isotype class-switching of B-cells to produce
IgE after allergen exposure. These cytokines also share a common receptor component, IL4Ra. We have investigated
five IL4RA single-nucleotide polymorphisms in a population of Dutch families ascertained through a proband with
asthma. By considering the probands and their spouses as an unrelated sample, we observed significant associations
of atopy and asthma-related phenotypes with several IL4RA polymorphisms, including S478P and total serum IgE
levels ( ). A significant gene-gene interaction between S478P in IL4RA and the51111 promoter variationPp .0007
in IL13, previously shown to be associated with BHR ( ), was detected. Individuals with the risk genotypePp .003
for both genes were at almost five times greater risk for the development of asthma compared to individuals with
both nonrisk genotypes ( ). These data suggest that variations in IL4RA contribute to elevated total serumPp .0004
IgE levels, and interaction between IL4RA and IL13 markedly increases an individual’s susceptibility to asthma.
Asthma is characterized by bronchial hyperresponsiveness
(BHR) and variable airways obstruction. Atopic traits
such as elevated total serum immunoglobulin E (IgE) lev-
els and positive skin responses are closely associated with
this disorder and may predict the development of symp-
tomatic asthma (Burrows et al. 1989, 1995; Sears et al.
1991). The interleukin-4 (IL4) receptor (IL4R [MIM
147781]), on chromosome 16p, is a key component in
the induction of the Th2 lymphocyte phenotype and IgE
production. A further role that IL4 plays in the patho-
genesis of asthma has been indicated from actively sen-
sitized Il4 knockout mice. Neither specific IgE induction
nor BHRwas detected in these mice (Brusselle et al. 1994,
1995), suggesting a critical role for the IL4/IL4R path-
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way in these phenotypes. Interleukin-13 (IL13 [MIM
147683]), on chromosome 5q, also contributes to the
maintenance of the Th2 lymphocyte profile that leads to
elevated baseline IgE levels, andmurinemodels have dem-
onstrated the critical nature of IL13 independent of IL4
(Grunig et al. 1998). The pleiotropic effects of IL13 and
IL4 are mediated through the IL4R, which is composed
of the high-affinity a subunit and either the common g
subunit or the IL13 receptor (IL13R) a subunit. The
IL13R is composed of one IL4Ra subunit and either a
low-affinity IL13Ra1 (Aman et al. 1996) or a high-affinity
IL13Ra2 subunit (Gauchat et al. 1997). The complete
IL4R is composed of an IL4Ra subunit and an IL4Rg
subunit. Therefore, it is possible that different polymor-
phisms in these receptors, as well as in the IL13 and IL4
cytokines, contribute to the complex regulation of atopy
or asthma phenotypes.
At least 16 single-nucleotide polymorphisms (SNPs) in
the IL4RA gene have been reported (Deichmann et al.
1997; Hershey et al. 1997; Mitsuyasu et al. 1998; Kruse
et al. 1999b; Ober et al. 2000; Hackstein et al. 2001).
The I50V, S478P, and Q551R variants have been asso-
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Table 1
Clinical Characteristics of Probands and Spouses in a Dutch
Population
Characteristic Probands Spouses
Sex (M:F) 124:76 76:125
Age (mean  SD) 52.1  8.4 51.0  9.2
Total IgE (geometric mean [IU]) 93.0 26.2
1 Positive skin test (%) 81.9 31.0
FEV1, predicted premedication (% [mean]) 69.6 98.4
Reversibility, 15% (% [baseline]) 59.4 6.5
BHRa, PC20 32 mg/ml (%) 88.2 25.6
NOTE.—Total sample population consisted of 200 probands and
201 spouses. Different numbers for the SNPs in the following tables
are due to missing genotype data.
a Thirty probands were not retested owing to an FEV1 that was too
low ( predicted) to be tested safely.FEV  40%1
ciated with a greater risk for atopy (Hershey et al. 1997;
Kruse et al. 1999b), a greater risk for atopic asthma (Mit-
suyasu et al. 1998), and variation in IgE levels (Kruse et
al. 1999b). In addition, specific variants were shown to
modulate the activity of IL4RA (Hershey et al. 1997;
Deichmann et al. 1998) and the levels of soluble IL4RA
(Hackstein et al. 2001). Eight polymorphisms in IL4RA
(seven in exon 12) were studied in inbred and ethnically
diverse outbred populations, and significant evidence for
an association between several of these variants, as well
as the resulting haplotypes, and asthma and atopy was
obtained (Ober et al. 2000). We evaluated five polymor-
phisms (four in exon 12) in IL4RA in a Dutch popula-
tion that was ascertained through a proband with asth-
ma, to determine the importance of these variants in
regard to susceptibility to and expression of asthma and
atopy in this population. On the basis of the biological
role of IL4R, our primary hypothesis was that differences
in total serum IgE levels may be due to different IL4RA
genotypes.
Considering the biological interaction between IL13
and IL4R, we also sought to examine the potential gene-
gene interaction between IL13 and IL4RA. We previ-
ously reported that the 1111 C/T variant of IL13 con-
tributes significantly to BHR and asthma susceptibility
( and , respectively) but not to totalPp .003 Pp .005
serum IgE levels (Howard et al. 2001). IL4RA has pre-
viously been associated with numerous atopic condi-
tions. Since asthma is a disease characterized by BHR
and allergic responses, we hypothesized that individuals
with the risk genotypes for both of these genes would
have a greater risk for asthma.
Probands with clinical asthma were originally char-
acterized between 1962 and 1975 (Panhuysen et al.
1998; Xu et al. 2000). Between 1990 and 1998, 200
probands, their spouses, children and available grand-
children were studied. All individuals underwent spi-
rometry, reversibility to 800 mg albuterol, and bronchial
responsiveness testing to histamine (Panhuysen et al.
1998). Skin testing was performed with 16 common
aeroallergens (Panhuysen et al. 1998), and total serum
IgE levels were measured (Xu et al. 2000). The probands
and spouses represent an appropriate unrelated sample
for association studies and were similar in age, which
removes the possible confounding effect that age has on
changes in BHR, in IgE, and in atopy. This study was
approved by the Medical Ethics Committees of the Uni-
versity Hospital, Groningen, andWake Forest University
School of Medicine. All case subjects gave written in-
formed consent.
The probands and spouses were of similar ages (mean
ages were 52.1 years and 51.0 years, respectively) (table
1). All probands were BHR positive at the time of initial
testing; 11.1% of those retested were no longer BHR
positive. Approximately 43% of the probands had high
levels of BHR ( mg/ml). Although the probandsPC  220
were not selected for atopy, 81.9%, compared to 31.0%
of the spouses, had at least one positive skin test.
IL4RA contains 12 exons and spans a genomic dis-
tance of ∼51 kb (Kruse et al. 1999a). We chose to eval-
uate five polymorphisms that previously had been shown
to be associated with asthma- or allergy-related pheno-
types. All of these polymorphisms, except I50V, are
within a 528-bp interval in exon 12. The I50V poly-
morphism encodes the extracellular portion of the re-
ceptor molecule and is located ∼20 kb upstream from
this region.
For the I50V, E375A, and C406R polymorphisms,
PCR was performed using standard conditions and by
the primers described elsewhere (Mitsuyasu et al. 1998),
for I50V, or the primers 5′-CAGCATGGTGCCCAGTG-
GAG-3′ and 5′-CTTGGGAACTCATCCCAGGGC-3′,
for E375A and C406R. The E375A and C406R poly-
morphisms were contained within the same 334-bp PCR
product and were digested with the restriction enzymes
Cac8I (E375A) or Tsp45I (C406R), to distinguish the
alleles. The I50V PCR products were digested with the
restriction enzyme MslII. The S478P and Q551R poly-
morphisms were genotyped using a variation of allele-
specific PCR that utilizes fluorescent dye and automated
sequencer technology called “fluorescent allele-specific
PCR” (Howard et al. 1999). Allele-specific primers were
designed for both polymorphisms by use of the known
IL4RA sequence (GenBank accession number X52425)
and previously published data (Hershey et al. 1997;
Kruse et al. 1999b). Two allele-specific forward primers
were designed with different fluorescent labels and an
addition of two nucleotides to one. The S478-specific
primer was (tetrachloro-fluorescein and 6-carboxy-
fluorescein) 5′-TGCTTACCGCAGCTTCAGCAACT-3′,
and the P478-specific primer was (6-carboxy-fluores-
cein) 5′-CTTACCGCAGCTTCAGCAACC-3′. The com-
mon reverse primer was 5′-TTTCTGGCTCAGGTTGG-
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Table 2
Association between log(IgE) Levels and IL4RA Polymorphisms in
Dutch Study
Polymorphism N
Geometric
Mean
(IU/ml)
log(IgE)a
(Mean  SD) P
I50V: .07
II 65 34.7 1.54  .66
IV and VV 155 53.7 1.73  .71
E375A: .02
EE 258 56.2 1.75  .74
EA and AA 75 34.7 1.54  .63
C406R: .01
CC 259 55.0 1.74  .74
CR and RR 74 32.4 1.51  .65
S478P: .0007
SS 204 64.6 1.81  .72
SP and PP 81 31.6 1.50  .6
Q551R: .06
QQ 226 53.7 1.73  .73
QR and RR 113 38.0 1.58  .69
a log(IgE) levels were adjusted for age and sex and were analyzed
for the genotypes “1/1” versus “1/2 and 2/2.”
GGC-3′. The forward primer specific for the Q551 allele
was (tet) 5′-GGCCCCCACCAGTGGCTATCA-3′, and
the primer specific for the R551 allele was (fam) 5′-CCC-
CCACCAGTGGCTATCG-3′. The same reverse primer,
5′-CCAGTCCAAAGGTGAACAAGGGG-3′, was used
to detect each of the allele-specific products. Fragments
were separated and analyzed by ABI 377 DNA sequenc-
ers. The IL13 1111 promoter SNP was genotyped us-
ing a PCR-RFLP assay by the primers 5′-ATGCCTTGT-
GAGGAGGGTCAC-3′ and 5′-CCAGTCTCTGCAGG-
ATCAACC-3′. PCR products were digested with NheI
(New England Biolabs), and the alleles were resolved by
electrophoresis on a 2% agarose gel.
The allele frequencies for the five IL4RA SNPs from
this Dutch population were 0.47, for V50; 0.12, for
A375; 0.12, for R406; 0.16, for P478; and 0.20, for
R551. Each polymorphism was in Hardy-Weinberg
equilibrium, and significant ( ) linkage disequi-5P ! 10
librium (LD) between E375A, C406R, S478P, and
Q551R was observed (Zaykin et al. 1995). LD between
these four polymorphisms and the I50V polymorphism
was not observed. These results are consistent with those
reported by Ober et al. (2000). The most common hap-
lotype was E375, C406, S478, and Q551. Owing to the
nearly complete LD between the four exon 12 SNPs,
haplotypes did not improve the evidence for individual
association with the S478P polymorphism (data not
shown).
Analysis was performed first for total serum IgE levels,
then for skin-test responsiveness to common allergens,
for asthma, and for BHR. Total serum IgE was analyzed
as a quantitative trait, after being logarithm trans-
formed, to approximate a normal distribution, and being
age and sex adjusted. Differences between groups were
tested by ANOVA, t test, and multiple-regression anal-
ysis. Individuals were considered responsive to an aller-
gen skin test, if one or more test showed a mean wheal
diameter 5 mm. For BHR, case subjects were defined
as all probands and spouses with a 32 mg/ml his-PC20
tamine. The control group for both BHR-positive and
asthma case subjects was comprised of BHR-negative
spouses ( mg/ml). Each of the biallelic poly-PC 1 3220
morphisms was analyzed by comparing differences, be-
tween case subjects and controls, of genotype frequen-
cies. Assuming a dominant model, because of the small
number of homozygotes for the rare allele, tests were2x
performed. No corrections were made for multiple com-
parisons for three reasons: first, because of the biological
role that IL4RA plays, our primary hypothesis was that
mean IgE levels would differ between genotypes; second,
since the phenotypes tested (asthma, BHR, total serum
IgE levels, and skin-test response) are strongly associated
with each other in this population, the statistical analyses
do not represent independent tests; third, we performed
tests for association with phenotypes that have been ob-
served by other investigators, both to confirm previous
results and to better characterize asthma susceptibility
in our population. For the interaction analysis, P values
were determined by multiple-regression analysis, with
adjustments for age and sex.
A significant association between E375A, C406R,
and S478P and total serum IgE levels was observed
( ; table 2). S478P was also associatedPp .0007–.02
with skin responsiveness ( ; table 3). In each in-Pp .03
stance, the common allele (E375, C406, and S478) was
associated with higher total serum IgE levels and at least
one positive skin test. S478P was the only variation as-
sociated with BHR or asthma ( ; table 3).Pp .02–.04
More of the BHR-positive individuals were homozygous
for the S478 allele than BHR-negative individuals.
The SNPs with the strongest evidence for association
for IL4RA (S478P with total serum IgE levels) and IL13
(1111 C/T with BHR; Howard et al. 2001) were ex-
amined for potential gene-gene interaction for asthma
susceptibility. Individually, each SNP was significantly
associated with the asthma phenotype. An interaction ef-
fect was observed in individuals with the risk genotypes
for both IL4RA and IL13 (odds ratio ;[OR]p 4.87
; fig. 1). This effect was most notable in thosePp .0004
individuals homozygous for the common allele for
IL4RA (recessive effect) and in those individuals with
the rare allele for IL13 (dominant effect), consistentwith
the results for the individual SNPs (fig. 1). A similar
analysis examining total serum IgE levels was per-
formed. In this analysis, the interaction between the two
genes was significant ( ) but was similar to thePp .005
effect of IL4RA S478P alone ( ).Pp .0007
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Table 3
Association between Asthma and Atopic Phenotypes and IL4RA Polymorphisms in Dutch Study
Polymorphism Asthma (Frequency) BHR (Frequency)
No. of Positive
Skin Test(s) (Frequency)
Probands
(n p 109)
BHR-Negative Spouses
(n p 87)
mg/mlPC  3220
(np 126)
mg/mlPC 1 3220
(n p 94)
1
(n p 116)
0
(n p 105)
I50V:
II .28 .29 .29 .30 .26 .33
IV .49 .48 .46 .49 .48 .47
VV .24 .23 .25 .21 .26 .20
P P P
.85 .79 .16
Probands
(np 150)
BHR-Negative Spouses
(n p 112)
mg/mlPC  3220
(n p 178)
mg/mlPC 1 3220
(np 124)
1
(n p 166)
0
(n p 137)
E375A:
EE .81 .71 .81 .73 .82 .72
EA .16 .28 .16 .26 .16 .26
AA .03 .01 .03 .01 .02 .01
P P P
.06 .16 .09
Probands
(n p 148)
BHR-Negative Spouses
(np 108)
mg/mlPC  3220
(n p 175)
mg/mlPC 1 3220
(np 120)
1
(n p 162)
0
(n p 134)
C406R:
CC .82 .71 .82 .73 .82 .73
CR .16 .28 .16 .26 .16 .25
RR .03 .01 .02 .01 .02 .01
P P P
.05 .09 .05
Probands
(n p 144)
BHR-Negative Spouses
(np 103)
mg/mlPC  3220
(n p 171)
mg/mlPC 1 3220
(np 114)
1
(n p 160)
0
(n p 126)
S478P:
SS .77 .63 .75 .67 .77 .65
SP .20 .33 .22 .30 .20 .31
PP .03 .04 .03 .04 .03 .04
P P P
.02 .04 .03
Probands
(n p 151)
BHR-Negative Spouses
(np 114)
mg/mlPC  3220
(n p 181)
mg/mlPC 1 3220
(np 127)
1
(n p 169)
0
(n p 140)
Q551R:
QQ .68 .64 .68 .65 .69 .63
QR .26 .32 .25 .31 .25 .31
RR .05 .04 .07 .04 .05 .06
P P P
.48 .64 .2
This observation suggests a potential interaction that
may be important to the pathogenesis of asthma. We
have previously demonstrated that variants in IL13 con-
tribute significantly to BHR and asthma susceptibility
( and , respectively; Howard et al.Pp .003 Pp .005
2001) but not to total serum IgE levels. Here, we report
a significant association between variants in IL4RA and
elevated total serum IgE levels and an only-borderline-
significant association between variants in IL4RA and
BHR and asthma. More importantly, individuals with
the risk genotypes for both of these genes are muchmore
susceptible to asthma; common features of asthma in-
clude both elevated total serum IgE levels and BHR.
These data suggest that there is a genetic, as well as
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Figure 1 Interaction of IL4RA and IL13 genotypes. Bars indi-
cate the ORs between the different combinations of genotypes for
IL4RA (S478P) and IL13 (1111 C/T). The nonrisk genotype for
each gene was used as the reference OR.
biological, interaction between the IL4RA and IL13
gene products. The IL13 promoter polymorphism most
likely affects transcriptional regulation of the gene,
whereas it has been suggested that the S478P variation
of IL4RA alters the conformation of the receptor protein
and possibly modifies downstream signaling (Kruse et
al. 1999b). Increased amounts of IL13 cytokine may
enhance the effect of the altered IL4R complex, inten-
sifying the downstream response. Functional assays are
necessary to support this hypothesis.
Further evidence for the importance of IL4R in atopic
disorders and in asthma comes from recent therapeutic
reports of the use of soluble IL4R in these conditions
(Borish et al. 1999; Henderson et al. 2000). These re-
ports show that an IL4R antagonist can affect immu-
noglobulin synthesis and, in early clinical trials, can im-
prove respiratory function and asthma control. Our
results, in addition to other reports identifying IL4RA
as a key component of atopy or asthma-related pheno-
types, suggest that screening of this gene may identify
those individuals at risk for developing asthma, owing
to the IL13/IL4/IL4R pathway. This may lead to better
treatment efficacy by appropriate therapeutic interven-
tions, including soluble IL4RA. In addition, it will be of
interest to determine whether IL4RA polymorphisms af-
fect the response to an IL4R antagonist, as has been
shown with other pharmacogenetic relationships (Dra-
zen et al. 1999; Drysdale et al. 2000).
There is a large degree of variability in the results of
association studies with IL4RA polymorphisms. How-
ever, if only one or a few polymorphisms were analyzed,
it was unknown whether the effect observed was due to
LD to the “true” susceptibility allele. We did not observe
any evidence that I50V andQ551R are the primary poly-
morphisms responsible for allergy susceptibility. Instead,
our data suggest that the polymorphism associated with
asthma and atopic phenotypes is either E375A, C406R,
S478P, a combination of these loci, or an additional, as-
yet-unknown variant in LD with these polymorphisms
(as also concluded in other populations [Ober et al.
2000]). Our results are consistent with a previous study
reporting association of the P478 and R551 haplotype
with lower IgE levels (Kruse et al. 1999b). Because of
the strong LD between the exon 12 polymorphisms in
this population, it is impossible to determine without
functional data which, if any, is the true susceptibility
polymorphism. It is possible that a specific haplotype
induces conformational changes that together increase
the overall effect (Kruse et al. 1999b).
Asthma and allergy are conditions with complex im-
munologic, physiologic, and inflammatory etiologies. It
is apparent, on the basis of this and previous studies
(Hershey et al. 1997; Deichmann et al. 1998; Mitsuyasu
et al. 1998; Ober et al. 2000), that IL4RA contributes
to atopic phenotypes in at least some populations. In
addition, SNPs in IL13 have been associated with in-
creased risk for allergic asthma (van der Pouw Kraan et
al. 1999), higher total serum IgE levels (Graves et al.
2000; Liu et al. 2000) and asthma (Heinzmann et al.
2000; Howard et al. 2001). Functional studies exam-
ining the individual roles of IL13 and IL4 gene products
as well as their biologic interactions and the resulting
downstream responses will provide valuable insight into
the overall mechanisms that cause susceptibility to
asthma and to atopy.
In summary, this study provides evidence for a sig-
nificant interaction between IL4RA and IL13 that con-
tributes to asthma susceptibility. In addition to the in-
teraction, our results support observations in other
populations suggesting that polymorphisms in IL4RA
alone are associated with asthma- and atopy-related phe-
notypes. Increased total serum IgE levels were signifi-
cantly associated with three of the five polymorphisms
in the gene that were tested. In the same manner, ad-
ditional genes in the same pathway, such as IL4, STAT6,
and JAK1,may also contribute to the genetic interaction
and account for an additional risk for asthma in specific
individuals.
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